drugset / Trial / NCT06318871
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Phase 0
Active not recruiting
5 enrolled
Dana-Farber Cancer Institute
Kidney Cancer Association · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma. Names of the study therapies involved in this study are/is: * CIML NK cell therapy (a NK cell therapy) * IL-2 (a type of cytokine)
Timeline
- Start
- 2024-08-28
- Primary completion
- 2027-02-28
- Completion
- 2031-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | — | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | — | — |